Physicians push back against statin memory warning

 

Following a review of 25 clinical trials, some researchers have said the Food and Drug Administration's warning that statins could affect memory and cognition is questionable.

The FDA says labels on statin packaging should warn users of cognitive changes related to attention span, problem solving, memory or language.

The review was led by Brian R. Ott, M.D., director of the Alzheimer's Disease & Memory Disorders Center at Rhode Island Hospital and professor at the Alpert Medical School of Brown University.

Findings appeared in the Journal of General Internal Medicine.

The review “found no significant effect of statin use on the mental capacity of people with normal brain functioning or even those with Alzheimer's disease. The results suggest that the FDA's statin warning should be re-evaluated.”